Neuromed CEO Christopher Gallen: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec talks about the firm's pipeline, licensing and the possibility of going public.
You may also be interested in...
Merck Signs On For Neuromed’s Chronic Pain Agent
Merck could pay up to $450 mil. for the class of oral N-type calcium channel blockers.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.